Benitec & Big Pharma

Before and after the Axovant collaboration OPMD must have attracted a lot of interest from many different companies who saw the value of a promising, bolt-on, orphan-designated acquisition. With amateurish Axovant out of the way a new sophisticated suitor may have stepped in to collaborate or buy our OPMD program. Perhaps this is why there has been an extended period of radio silence from the company as due diligence is conducted and the program valued to include the improved delivery system.